Physician profile
David B Hammes
NPI 1588745756
$5,484.82
in general payments reported to CMS, 2019-2025
20 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $654 · 2021: $1,047 · 2022: $1,047 · 2023: $849 · 2024: $667 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,989.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,719.74 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $521.49 | 2022-2025 | Infuse, Infuse Multifocal, Xiidra |
| Alcon Vision LLC | $411.97 | 2019-2025 | Rocklatan, Total30, Precision7 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $343.22 | 2019-2021 | |
| Coopervision INC. | $292.54 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $196.14 | 2019-2024 | |
| Dompe US, INC. | $165.03 | 2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $156.29 | 2020-2023 | |
| Allergan, INC. | $137.93 | 2019-2022 | |
| Horizon Therapeutics Plc | $135.04 | 2022-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $94.25 | 2021-2022 | |
| Oyster Point Pharma, INC. | $93.11 | 2022-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $60.76 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $42.14 | 2024-2025 | Xdemvy |
| Alcon Research LLC | $26.65 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $24.77 | 2019-2020 | |
| Misonix INC | $20.54 | 2019 | |
| Plexus Optix, INC. | $16.19 | 2021 | |
| Shire North American Group INC | $14.33 | 2019 | |
| Optos, INC. | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hammes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.